Clinical Trial Update: Contribution of Dolutegravir to Obesity and Cardiovascular Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the contribution of dolutegravir to obesity and cardiovascular disease in HIV-1 infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abnormality of Adipose Tissue
• Body Fat Disorder
• Body Weight Changes
• Cardiovascular Disease
• HIV Infection
• Lipodystrophy Syndrome
• Obesity

Drugs mentioned

• Dolutegravir (dolutegravir)

Snippet

Sponsor: Augusta University | Conditions: HIV-1-infection, Antiviral Drug Adverse Reaction | Phase 4 | Status: COMPLETED